{"id":2488,"date":"2024-07-09T10:57:02","date_gmt":"2024-07-09T02:57:02","guid":{"rendered":"https:\/\/flcube.com\/?p=2488"},"modified":"2024-10-16T00:22:18","modified_gmt":"2024-10-15T16:22:18","slug":"eli-lilly-co-to-acquire-morphic-holding-inc-in-a-usd-3-2-billion-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=2488","title":{"rendered":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal"},"content":{"rendered":"\n

Eli Lilly & Co. (NYSE: LLY<\/a>), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2 billion. Shareholders of Morphic will receive USD 57 per share, which represents a 79% premium over the biotech’s recent closing price. The acquisition has been approved by the boards of both companies and is anticipated to be fully completed by the third quarter of 2024.<\/p>\n\n\n\n

Lilly’s interest in Morphic is largely due to the latter’s pipeline of oral small-molecule integrin therapies. MORF-057, a selective inhibitor of \u03b14\u03b27 integrin, is at the forefront of this pipeline and is currently under development for the treatment of inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease. MORF-057 is being evaluated in Phase II studies for these conditions. The drug was developed using Morphic’s proprietary MInT technology platform, which underscores the company’s expertise in integrin structure and biology. In addition to MORF-057, Morphic’s preclinical pipeline encompasses molecules targeting autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases, and cancer.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911],"class_list":["post-2488","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"\nEli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2 billion. Shareholders of Morphic will receive USD 57 per share, which represents a 79% premium over the biotech's recent closing price. The acquisition has been approved by the boards of both companies and is anticipated to be fully completed by the third quarter of 2024.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=2488\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=2488\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-09T02:57:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-15T16:22:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal\",\"datePublished\":\"2024-07-09T02:57:02+00:00\",\"dateModified\":\"2024-10-15T16:22:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488\"},\"wordCount\":216,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2488#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=2488\",\"name\":\"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2024-07-09T02:57:02+00:00\",\"dateModified\":\"2024-10-15T16:22:18+00:00\",\"description\":\"Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2 billion. Shareholders of Morphic will receive USD 57 per share, which represents a 79% premium over the biotech's recent closing price. The acquisition has been approved by the boards of both companies and is anticipated to be fully completed by the third quarter of 2024.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=2488\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=2488#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal - Insight, China's Pharmaceutical Industry","description":"Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2 billion. Shareholders of Morphic will receive USD 57 per share, which represents a 79% premium over the biotech's recent closing price. The acquisition has been approved by the boards of both companies and is anticipated to be fully completed by the third quarter of 2024.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=2488","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=2488","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-07-09T02:57:02+00:00","article_modified_time":"2024-10-15T16:22:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=2488#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=2488"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal","datePublished":"2024-07-09T02:57:02+00:00","dateModified":"2024-10-15T16:22:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=2488"},"wordCount":216,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Eli Lilly","NYSE: LLY"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=2488#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=2488","url":"https:\/\/flcube.com\/?p=2488","name":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2024-07-09T02:57:02+00:00","dateModified":"2024-10-15T16:22:18+00:00","description":"Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has announced that it has entered into a definitive acquisition agreement with fellow U.S. firm Morphic Holding Inc. (NASDAQ: MORF). Under the terms of the agreement, Lilly will acquire Morphic in a transaction valued at USD 3.2 billion. Shareholders of Morphic will receive USD 57 per share, which represents a 79% premium over the biotech's recent closing price. The acquisition has been approved by the boards of both companies and is anticipated to be fully completed by the third quarter of 2024.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=2488#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=2488"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=2488#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly & Co. to Acquire Morphic Holding Inc. in a USD 3.2 Billion Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2488","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2488"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2488\/revisions"}],"predecessor-version":[{"id":6881,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/2488\/revisions\/6881"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2488"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2488"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2488"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}